Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demonstrated that the addition of taxanes to anthracycline-based chemotherapy improves the outcome in either concurrent or sequential schedule. Nowadays, the TAC regimen (docetaxel, doxorubicin and cyclophosphamide) is a standard treatment in both node-positive and high-risk node-negative early breast cancer. Doxorubicin and epirubicin are equivalent, but at similar doses epirubicin appears to have a better side effects profile than doxorubicin in terms of myelosuppression and cardiotoxicity. We conducted a retrospective study to establish the role of TEC (epirubicin) regimen in adjuvant setting. Methods: Pre-or post-menopausal women, with stage I-III breast cancer, PS ECOG 0-2 and normal left ventricular ejection fraction, were eligible. TEC chemotherapy at median doses of docetaxel 75 mg/m
Introduction
In the United States, breast cancer is the most common female malignancy, excluding cancers of the skin, and it is the second leading cause of cancer death in women, after lung cancer [1] . In Italy, the estimated incidence and mortality rates for breast cancer are 114 and 24 per 100,000 inhabitants per year, respectively [2] . However, the breast cancer early diagnosis, performed by screening programs, and the adjuvant combined treatments may improve the disease free survival (DFS) and overall survival (OS).
Adjuvant chemotherapy represents a standard of care for this pathology and in the last 30-40 years we have assisted to some significant changes. The addition of anthracyclines and taxanes to adjuvant chemotherapy, in different combinations (concurrent or sequential), had a big impact on the natural history of the breast cancer [3] [4] [5] .
Two randomized phase III studies investigated the use of a three-drug combination known as TAC chemotherapy (docetaxel, doxorubicin and cyclophosphamide) versus the FAC chemotherapy (5fluouracil, doxorubicin and cyclophosphamide) in the adjuvant setting of early breast cancer, either node-positive or node-negative at high-risk of recurrence, with benefit in both DFS and OS [6, 7] . TAC regimen improves the outcome; on the other hand it also increases the risk of toxicity.
In view of the high and frequent toxicity associated to TAC regimen, we carried out a retrospective study to explore the hypothesis that TEC regimen substituting doxorubicin with epirubicin may improve tolerability.
Patients and methods

Eligibility
Pre-or post-menopausal women with histologically confirmed breast cancer, no evidence of distant metastases, aged 18 years, Eastern Cooperative Oncology Group scale (ECOG) performance status (PS) 2, normal left ventricular ejection fraction (LVEF 51%) as assessed by echocardiogram, adequate hematological, renal and hepatic function, were eligible for the study; no previous chemotherapy nor radiotherapy was permitted. Cardiac toxicity was defined as LVEF decrease 20% points from baseline; LVEF was measured at baseline and at the end of chemotherapy, thereafter every 6 months. For all patients, the following variables were recorded: sex, age, performance status according to ECOG scale, type of tumor (CDI or CLI), stage of disease, grading, hormone receptor status and HER-2 status by IHC and/or FISH test. Patients and disease characteristics are shown in Table 1 . 
Treatment schedule
Premedication with antiemetics and steroids was planned systematically. Treatment schedule and dose reduction protocol were chosen at discretion of investigator. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was proposed to overall population for a potential risk of febrile neutropenia 20%. Dexrazoxane prophylaxis was chosen at discretion of the attending physician. Each patient received the TEC regimen at 
Statistical analysis
The primary endpoint was the incidence of grade 3-4 toxicity; hematological and non-hematological toxicity was recorded according to NCI Common Toxicity Criteria, version 3.0 [8] . When planning this retrospective study, we estimated that at least 33 patients were needed in order to detect incidence rates of 25% or lower with a maximum acceptable error of 15%. Patients' toxicities were reported as absolute numbers and percentages, together with their 95% confidence intervals (CI). Continuous variables were described by using median and range or by mean and standard deviation (SD). Each patient was analyzed for the frequency of drug toxicity, dose reduction or delay.
The secondary endpoints were disease free survival (DFS) and overall survival (OS). Disease free survival was defined as the interval from the start date of chemotherapy to the date of first loco-regional or metastatic relapse; diagnosis of a secondary cancer (excluding no-melanoma cancer); last follow up visit if disease had not progressed.
Overall survival was defined as the interval between the beginning of treatment and death for any cause or last follow up visit. For the purpose of our analysis DFS and OS were limited to a three years follow up period. Survival probabilities were calculated according to Kaplan-Meier product limit estimator and were presented together with their 95% (CI) estimates [9] . Statistical analysis was carried out by using SPSS software, version 17.0 (SPSS Inc, Chicago, IL).
Results
Toxicity
The data of 33 consecutive female patients with early and/or operable breast cancer, underwent adjuvant TEC chemotherapy between February 2008 and June 2010 at the Division of Oncology of the Hospital "Bolognini" of Seriate (Bergamo, Italy), were retrospectively collected and monitored until June 2012. The median age was 57 years (range 47-73). All patients received at least one cycle of chemotherapy and were evaluable for toxicity. A total of 186 courses were given, with a median of 6 cycles (range, 2-6) per patient. The 87.9% of patients completed the treatment program. Just four (12.1%) chemotherapies were prematurely interrupted: two (6.1%) for adverse reaction to docetaxel, one (3.0%) for relapse disease and one (3.0%) in accordance to the will of the patient. In 7/33 (21.2%) of cases a dose reduction was performed, with an overall mean dose-chemotherapy reduction of 4.1% (Table 4) . These patients needed also a chemotherapy interval prolongation, with a mean delay of 10.1 days (5 patients for neutropenia G3-4, 1 patient for febrile neutropenia and 1 patient for diarrhea G3-4).
The vast majority of patients (94%) received a primary G-CSF prophylaxis (pegylated form in 29 patients and no-PEG in 2 patients); two patients did not accept primary G-CSF prophylaxis and did not develop myelotoxicity.
In our study the incidence of grade 3 or 4 neutropenia was 21.2% (95% CI, 9.8-37.5); febrile neutropenia was observed in just one patient (3.0%; 95% CI, 0.1-14.0), with subsequent hospitalization and full recovery. Twentytwo patients (66.6%) underwent primary dexrazoxane prophylaxis, however, cardiotoxicity was absent in both subgroups (0%; 95% CI, 0-8.7%). Two cases (6.1%; 95% CI, 1.0-18.6) of major allergic reaction G3 to docetaxel (generic drug) were observed. No treatment-related death was seen. Overall, the incidence of grade 3 or 4 no hematologic adverse events (AEs), regardless of type, was very low. All grades and 3-4 grades treatment-related AEs are shown in Table 5 . Abbreviations: CI: confidence interval; § Cardiac toxicity: it was defined as LVEF decrease ≥20% points from baseline; LVEF was measured at baseline and at the end of chemotherapy, thereafter every 6 months.
Survival
At a median follow-up of 32 months (range 11-36), one patient (3.0%) developed primary pancreatic tumor and two patients (6.1%) had relapsed: one patient had a pulmonary recurrence and one patient a liver recurrence. Two of 33 patients (6.1%) died, one (3.0%) for breast cancer relapse and one (3.0%) for a secondary cancer. At the time of analysis, the median time to relapse and death was not reached. After 32 months, the estimated 3-year DFS rate was 89.9% (95% CI, 79.0-100) and the 3-year OS rate was 93.8% (95% CI, 85.6-100), as shown in Figures 1  and 2 , respectively.
Discussion
Adjuvant therapy's benefits are well known in early and operable breast cancer. Several meta-analyses have showed higher efficacy in DFS and OS of anthracyclines and taxanes chemotherapy combinations, either concurrent and cyclophosphamide 500 mg/m 2 IV on day 1 every 3 weeks for 6 cycles), proved the superiority of docetaxelbased chemotherapy in both node-positive and high-risk node-negative early breast cancer, but at the cost of a greater toxicity [6] [7] .
BCIRG 005 trial, comparing TAC combination with ACT sequential regimen (doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 IV on day 1 every 3 weeks for four cycles, followed by four cycles of docetaxel 100 mg/m 2 IV every 3 weeks), demonstrated equal efficacy but with different toxicity profile [14] .
The two most commonly used anthracyclines are doxorubicin and epirubicin. Anyway, even if doxorubicin and epirubicin are equivalent in terms of efficacy, at similar doses the epirubicin appears to have a better side effects profile than doxorubicin in terms of myelosuppression and cardiotoxicity. More specifically, the equimolar dose ratios of doxorubicin to epirubicin for myelosuppression and cardiotoxicity are 1:1.2 and 1:1.7-2.0, respectively [16] .
They are known to cause both short-and long-term cardiotoxicity, including potentially fatal congestive heart failure (CHF). The median cumulative doses at which the two drugs can cause congestive heart failure are respectively 492 mg/m 2 for doxorubicin and 1134 mg/ m 2 for epirubicin [17] . The mechanism of cardiotoxicity induced by anthracyclines is not fully understood, however, some pharmacological and toxicological data suggest that cardiotoxicity is caused by the interaction between the anthracycline and the iron ions with the consequent formation of complexes which mediate a cytotoxic mechanism on the myocardium [18] . In support of this mechanism, the use of a substance such as iron chelator dexrazoxane reduces the risk of anthracycline cardiotoxicity [17] .
Epirubicin has a lower propensity to produce myelotoxic and cardiotoxic effects than doxorubicin, and its recommended maximum cumulative dose is almost double that of doxorubicin, thus allowing for more treatment cycles and/or higher doses of epirubicin [19] .
In view of the high and frequent toxicity associated to TAC regimen, we performed this retrospective study to explore the hypothesis that the use of epirubicin rather than doxorubicin can improve tolerability.
The incidence of grade 3-4 toxicity reported in our study with TEC regimen was very low as compared to that of phase III trials with TAC regimen (BCIRG 001, GEICAM 9805 and BCIRG 005) [6] [7] 14] . In particular, grade 3-4 neutropenia and febrile neutropenia (FN), which are usually the most frequent side effects of TAC regimen, were observed in only 21.2% (95% CI, 9.8-37.5) and 3% (95% CI, 0.1-14.0) of our patients, respectively (Tables 5, 6 and 7). In the above mentioned phase III studies, the grade 3-4 neutropenia varied between 50.8-65.5% and febrile neutropenia between 9.6-28.8% (Table 6 ). Primary G-CSF prophylaxis was permitted in the BCIRG 005 trial but not in BCIRG 001 and GEICAM 9805 trials [14, [6] [7] ; however, owing to an incidence of neutropenic fever of more than 25% in the TAC group, the protocol in the GEICAM 9805 was amended after 230 patients enrolled [7] .
In a randomized phase II trial, AERO B03 trial, the "standard" control arm was TEC regimen: docetaxel 75 mg/ m 2 (T), epirubicin 75 mg/m 2 (E) and cyclophosphamide 500 mg/m 2 (C) IV on day 1 every 3 weeks for 6 cycles. Grade 3-4 neutropenia occurred in nine (26%) patients and febrile neutropenia in four (11%) patients; no one cardiac failure was registered [20] . These rates are more similar but slightly higher than those of our study (Table  6 ).
According to recent indications of ASCO, NCCN and EORTC guidelines [21] [22] [23] , the prophylactic administration of growth factors is recommended in all patients undergoing chemotherapy with an expected incidence of FN 20%. More specifically, the risk of febrile neutropenia associated with TAC schedule is estimated to be 23.8% [24] . The rate of febrile neutropenia was 25.2% among the 111 patients who did not receive primary prophylaxis and 5.5% among the 421 patients who received primary G-CSF prophylaxis [7] ; η Primary prophylaxis was delivered in just 17% of patients of TAC group [14] ; θ Primary prophylaxis was delivered in the 80% of patients [20] ; ι Primary prophylaxis was delivered in the 94% of patients. Table 7 Comparison between current and previous studies with similar median follow up BCIRG 001 (interim analysis) [26] Hungarian experience (BCIRG 001) [27] BCIRG 005 (interim analysis) [28] Current study So, the incidence of severe neutropenia and NF in our study was extremely lower than in others (21.2% and 3%, respectively); it was likely due to the substitution of doxorubicin with epirubicin, to a lower median doses of epirubicin (60 mg/m 2 ) and primary G-CSF prophylaxis in the most of our patients (94%).
As regards cardiotoxicity, in our retrospective study 66% of patients underwent primary dexrazoxane prophylaxis; anyway, none of the patients at a 32 months follow up developed sub-clinical or clinical congestive cardiac failure or any other short-and long-term adverse effects so far, with no difference between the two subgroups (0%; 95% CI, 0-8.7%) ( Tables 5, 6 and 7) . Furthermore, these observations are consistent with the findings of previous trials when a more similar median follow up, from 30 to 33 months, is considered [26] [27] [28] (Table 7) .
Percentages of other grade 3-4 side effects were very low, about 0-3%, except for two episodes (6.1%; 95% CI, 1.0-18.6) of major allergic reaction G3 to docetaxel, that was slightly higher than in the other studies; these two patients did not received the standard premedication with dexamethasone at a dose of 8 mg orally twice a day for 3 days (6 doses) to reduce the risk of acute hypersensitivity reactions commonly associated with docetaxel therapy (Table 5) . A dose reduction was performed in just 21.2% of patients and the overall mean dose-chemotherapy reduction was 4.1% (Table 4) . Actually, the starting and final median doses in our trial do not change (Tables 2  and 3 ).
The thirty-two months follow up period considered in this study allowed us to analyze the DFS and OS data of the patients. The 3-year DFS and OS were 89.9% (95% CI, 79.0-100) and 93.8% (95% CI, 85.6-100), respectively (Figures 1 and 2 ).
The median doses of epirubicin used in our TEC regimen are lower than those commonly recommended (75, 90 and 100 mg/m 2 ). Epirubicin at doses of 50 mg/m 2 should be considered sub-optimal when compared to the 100 mg/m 2 dose [25] . [30] .
However, this probably is the first time that epirubicin at the dose of 60 mg/m 2 has ever been added to concurrent docetaxel-containing chemotherapy. Although the median follow up of the present study was too short to calculate median DFS and OS times, our estimated 3-year survival data resembled those observed in the trials using TAC regimen when a more similar median follow up is considered [26] [27] (Table 7) .
Conclusions
Our study has some limitations: it's a retrospective non-comparable trial and based on a small sample size. Chemotherapy doses and prophylactic treatments were chosen at investigator's discretion. The follow up was too short at the time of analysis. However, it may give us some suggestive indications. This study clearly shows that TEC (epirubicin 60 mg/m 2 ) treatment is associated to a very low risk of grade 3-4 toxicity. It has an acceptable and manageable toxicity as compared to both TAC and TEC (epirubicin 75 mg/m 2 ) regimens. It is feasible and well tolerated adjuvant chemotherapy in early and operable breast cancer. Our results are just exploratory, but indicate that TEC 60 mg/m 2 regimen could be selected for further assessments in randomized phase II and/or III trials.
